Consistently, our data revealed that PI3K/Akt signaling was significantly higher in metastatic colorectal cancers than in non-metastatic cancer, although both cancers exhibit a basal level of PI3K/Akt signaling (Figures 4A–E). This evidence concerns the gene AKT1 and metastatic colorectal cancer.